Table 4.

Multivariate analyses of risk factors for late transplant-related mortality

	number	RR	95% Conf Interval		p
Prior chronic GVHD
No prior diagnosis of cGVHD	3936	1.00
Prior cGVHD	3547	2.43	2.09	2.82	<0.0001
Acute GVHD History					<0.0001
None	4051	1.00
aGVHD in first 29 days post HCT	2446	1.40	1.21	1.63	<0.0001
aGVHD after day 29 post HCT	986	1.58	1.32	1.91	<0.0001
Disease Status at HCT					<0.0001
Early	4661	1.00
Intermediate	1823	0.93	0.78	1.10	0.3908
Late	999	1.43	1.20	1.69	<0.0001
HLA match					<0.0001
Sibling Donor	1861	1.00
Well Matched Unrelated	1412	1.39	1.15	1.67	0.0006
Partially matched Unrelated	1369	1.36	1.13	1.63	0.0013
Poorly matched Unrelated	841	1.56	1.25	1.93	<0.0001
TBI in the conditioning regimen
no	3186	1.00
yes	4292	1.47	1.27	1.70	<0.0001
Donor-recipient gender match					<0.0001
male -> male	2662	1.00
male -> female	1720	0.63	0.77	1.11	0.4146
female -> male	1629	1.55	1.32	1.83	<0.0001
female -> female	1472	1.11	0.93	1.33	0.2623
Graft source
Bone marrow	5354	1.00
Mobilized blood stem cells	2129	1.48	1.26	1.73	<0.0001

Factors tested, but not listed in table: Recipient age, sex, donor parity, donor-recipient CMV serology, use of ATG, GVHD prophylaxis, aGVHD grade, year of transplant, disease, platelet count at cGVHD diagnosis, serum bilirubin at cGVHD diagnosis, type of cGVHD onset, KPS/L at cGVHD diagnosis, severity of cGVHD at 1 year post-transplant, organ involvement of cGVHD at 1 year post-transplant